Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2001

01-01-2001 | Conference Report

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

Authors: Jane A. Cauley, Larry Norton, Marc E. Lippman, Stephen Eckert, Kathryn A. Krueger, David W. Purdie, Jordi Farrerons, Avraham Karasik, Dan Mellstrom, Kong Wah Ng, Jan J. Stepan, Trevor J. Powles, Monica Morrow, Alberto Costa, Sheryl L. Silfen, Erin L. Walls, Henry Schmitt, Douglas B. Muchmore, V. Craig Jordan

Published in: Breast Cancer Research and Treatment | Issue 2/2001

Login to get access
Metadata
Title
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
Authors
Jane A. Cauley
Larry Norton
Marc E. Lippman
Stephen Eckert
Kathryn A. Krueger
David W. Purdie
Jordi Farrerons
Avraham Karasik
Dan Mellstrom
Kong Wah Ng
Jan J. Stepan
Trevor J. Powles
Monica Morrow
Alberto Costa
Sheryl L. Silfen
Erin L. Walls
Henry Schmitt
Douglas B. Muchmore
V. Craig Jordan
Publication date
01-01-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006478317173

Other articles of this Issue 2/2001

Breast Cancer Research and Treatment 2/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine